Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$17.51 USD
-0.05 (-0.28%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $17.52 +0.01 (0.06%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CPRX 17.51 -0.05(-0.28%)
Will CPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Other News for CPRX
Catalyst Pharmaceuticals enters exclusive agreement with Kye Pharmaceuticals
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
Catalyst sells Canadian rights to Duchenne drug to Kye Pharma
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX): A Growth-Oriented Value Investment Opportunity